Cutaneous adverse effects of imatinib mesylate

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Cutaneous adverse effects of imatinib mesylate

A 52-year -old female patient was found to have elevated white blood cell count (WBC) on routine physical examination. Her WBC count was 67.260/ uL, hemoglobin was 8.3 gm/dL, hematocrit was 26.1% and platelet count was 133,000/uL. Bone marrow reveled myeloid hyperplasia and the Philadelphia chromosome was positive. Patient was diagnosed as chronic myeloid leukemia (CML) and imatinib mesylate tr...

متن کامل

Clinical pharmacokinetics of imatinib mesylate.

This review presents the clinical pharmacokinetics of imatinib mesylate. Aspects regarding absorption, tissue distribution, elimination and kinetic interactions are also discussed.

متن کامل

The teratogenic effects of imatinib mesylate on rat fetuses

Imatinib mesylate, a selective tyrosine kinase inhibitor, is the first line treatment against chronic myelogenous leukemia and gastrointestinal stromal tumors. The aim of the present study is to investigate the effects of imatinib mesylate on the pregnant rats and their fetuses. Pregnant rats were divided into three groups; the first group served as a control group. The second and third groups ...

متن کامل

Imatinib mesylate: A designer drug.

Molecularly targeted therapy is a novel approach in cancer treatment. Imatinib, a specific tyrosine kinase inhibitor, since its inception in 1990s, has become the first-line drug in management of chronic myelogenous leukemia (CML) chronic phase. It has also shown promising results in treatment of gastro-intestinal stromal tumors, clonal eosinophilic disorders and Philadelphia chromosome positiv...

متن کامل

Imatinib mesylate in polycythemia vera

In the September 15, 2003, issue of Blood,1 Oehler et al describe imatinib mesylate inhibition of the autonomous in vitro proliferation of peripheral blood– and bone marrow–derived polycythemia vera (PV) erythroid burst-forming units (BFU-Es). While their results superficially correlate with the previously published in vivo clinical observations of Silver,2 the conclusions of Oehler et al are a...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Northern Clinics of Istanbul

سال: 2015

ISSN: 2148-4902

DOI: 10.14744/nci.2014.88597